Autoimmune hemolytic anemias comprise of warm autoimmune hemolytic anemia (WAIHA), cold agglutinin disease (CAD), or mixed types. These patients rely heavily on transfusion medicine teams for testing (interpreting DATs, performing cold agglutinin titers and thermal amplitude testing) and supportive care (logistics of transfusion planning). Streamlining and standardizing diagnostics is key to the success of several clinical trials (Fostamatinib for WAIHA; Sutimlimab for CAD, etc.) which are ongoing or available for WAIHA and CAD; as is identifying who, when, and how to transfuse. Transfusion medicine physicians and scientists have also led the translational research arena to understand pathophysiologic mechanisms underlying these complex disorders. This session aims to discuss newer clinical therapies, perspectives in diagnostics, and supportive care by transfusion physicians/hematologists. In addition, the session will summarize the frontiers in translational science in immune hemolytic anemias so that the audience can be guided in diagnostics, supportive care, and other relevant advances.
Describe diagnostics and newer clinical therapies for autoimmune hemolytic anemias
Evaluate newer translational paths in autoimmune hemolytic anemia research
Summarize transfusion support for these patients with warm and cold agglutinin disease